Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: THAILAND - REVIEW
The macroenvironment is positive for the Thai pharmaceutical market. Politically, Yingluck Shinawatra became Thailand's first female Prime Minister in August 2011. Economically, the Economist Intelligence Unit (EIU) projects that Thailand will be the eighth largest economy in the Asia Pacific region by 2016. Legally, Thailand remains on the USTR's Priority Watch List in 2011. Demographically, the EIU projects an annual growth rate of around 0.7% up to 2016 and the population will be the ninth largest in the Asia Pacific region by 2016. The elderly population is rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region.
Despite relying heavily on imports, Thailand's pharmaceutical market is growing. The balance of pharmaceutical trade remains considerably negative, with retail medicaments accounting for over two-thirds of the total deficit. Between 2006 and 2010, the deficit in the balance of trade rose by a high double-digit CAGR. Thailand's pharmaceutical market is estimated to grow at a high single-digit CAGR in US dollar terms between 2011 and 2016. Thailand will have the eighth largest pharmaceutical market in the Asia Pacific region in 2016. In per capita terms, Thailand is projected to have the eighth highest rate in the Asia Pacific region by 2016.
The Thai generic sector is growing, especially in the public sector, where the government has encouraged its use over patented drugs in order to cut costs. Greater Pharma has recently launched its first generic inhaler drug for the treatment of osteoporosis, making it the first company in Southeast Asia to successfully manufacture a generic version of this drug. The Thai biologic sector is very underdeveloped, but there are signs that this could change. The government-backed organisation BIOTEC has formed partnerships with both Greater Pharma and i+MED. Greater Pharma has developed the first biologic allergy vaccine in Southeast Asia.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
